The major attraction of immunotherapy in oncology has been the sustained durable remissions. No other treatment within oncology, uh, really allows or gives that option to patients. Any of the other chemotherapy, targeted therapies, etc. the responses happen, but then, you know, for the most part, they are not what we call so-called curative or unlikely to induce long-term remissions. The big attraction of cytokine therapy has always been a limited duration of therapy, followed by the potential for long term remissions. The tolerability and the toxicity profile was uh fairly large and was significant, which uh sort of deterred a lot of patients and providers from using this therapy. However, now with newer forms and versions of uh cytokine therapy for IL2 specifically with Nembaleukin, there is a very good chance that we can induce these remissions and make the treatment widely applicable. So the first uh results of artistry one trial showed the tolerability, the toxicity profile was as noted before, there was some uh pyrexia, there was neutrophil count decrease, and some chills and nausea noted. However, the incidents of grade 3 and 4. Toxicities was fairly low and uh very tolerable regimen. Uh, the combination also uh was shown to be relatively well tolerated, and there was, there did not seem to be any overlap between the immune checkpoint therapy and uh the toxicity of namvolleukin. So going forward, I think novel ways of using cytokines and inducing, giving patients the potential to get these long term remissions is a very attractive way to develop immuno oncology. The immune checkpoint inhibitors have definitely made a big leap, however, we know that uh You know, everybody doesn't respond and the long term uh remission rates are relatively small still, so as well as there are a number of malignancies that do not respond to immune checkpoint inhibitors. So maybe. You know, the development of the cytokine therapies or multiple other types of cellular therapies, etc. offer that chance of maybe making the therapy more acceptable, widely applicable, and the potential for continuing to maintain efficacy with improved tolerability.
Presenter
